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1Department of Gene Manipulation virus (HIV) are obtained by posttranslational cleavage
of the Gag, Gag/Pol, and Env viral polyprotein precur-Institute of Molecular Genetics
Academy of Sciences of the Czech Republic sors. The Gag and Gag/Pol polyproteins, in particular,
are cleaved by a viral protease, which is itself containedFlemingovo nam. 2
166 37 Prague 6 within the Gag/Pol polyprotein chain. Since the demon-
stration that the human immunodeficiency virus prote-Czech Republic
2 Centre de Recherches sur les Macromole´cules ase (HIV Pr) is essential in the viral life cycle [1–3], this
enzyme has become one of the primary targets for anti-Ve´ge´tales (affiliated with Universite´ Joseph
Fourier)-CNRS BP53 viral drug design. This has led to the development of
many active-site inhibitors, some of which are currentlyF38041 Grenoble Cedex
France in use as therapeutic agents for AIDS treatment [4]. In
order to be proteolytically active, two protease monomers3 European Synchrotron Radiation Facility
BP220 must assemble into a homodimer, with each subunit
contributing residues to the substrate binding pocket,F38043 Grenoble Cedex
France including residue Asp-25, which is directly involved in
the catalysis [5]. The requirement for protease dimeriza-4 Unite´ d’Immunologie Structurale
(URA 1961 CNRS) tion to achieve proteolytic activity has led several au-
thors to propose alternative noncompetitive inhibitorsDe´partement d’Immunologie
Institut Pasteur that would provoke the dissociation of the active homo-
dimeric assembly [6–8].75724 Paris Cedex 15
France With the objective of probing the structural stability
of HIV Pr and the eventual design of potential inhibitors
of the enzyme that are directed to regions other than
the active site, we have examined the effects of anti-Summary
HIV-1 Pr monoclonal antibodies (mAbs) on the catalytic
activity of the protease [9, 10]. We have recently reportedBackground: Since the demonstration that the prote-
ase of the human immunodeficiency virus (HIV Pr) is a preliminary study of mAb1696, which, although raised
against the HIV-1 Pr, inhibits the catalytic activity of bothessential in the viral life cycle, this enzyme has become
one of the primary targets for antiviral drug design. The the HIV-1 and HIV-2 enzymes with inhibition constants
of 0.6 nM and 1.5 nM, respectively, at pH 7.4 [11]. Thismurine monoclonal antibody 1696 (mAb1696), produced
by immunization with the HIV-1 protease, inhibits the study also showed that mAb1696 cross-reacts with pep-
tides containing the N terminus of the HIV protease. Thecatalytic activity of the enzyme of both the HIV-1 and
HIV-2 isolates with inhibition constants in the low nano- N-terminal region accounts for a large percentage of the
interface between the two HIV Pr monomers because itmolar range. The antibody cross-reacts with peptides
that include the N terminus of the enzyme, a region that interdigitates with the C-terminal segment from the
other monomer, thus forming a 4-stranded intermolecu-is highly conserved in sequence among different viral
strains and that, furthermore, is crucial for homodimer- lar -pleated sheet in the active homodimer. We pro-
posed that mAb1696 inhibits HIV Pr by perturbing theization to the active enzymatic form.
native structure of the enzyme at the dimer interface
[11]. In addition, a clustering of negatively charged resi-Results: We report here the crystal structure at 2.7 A˚
resolution of a recombinant single-chain Fv fragment of dues at the antigen binding site was observed in the
unliganded Fab crystal structure, which suggested thatmAb1696 as a complex with a cross-reactive peptide
of the HIV-1 protease. The antibody-antigen interactions electrostatic forces play an important role in the interac-
tion between mAb1696 and HIV Pr.observed in this complex provide a structural basis for
understanding the origin of the broad reactivity of mAb- To investigate further the mechanism of HIV Pr inhibi-
tion by mAb1696, we have now expressed a single-1696 for the HIV-1 and HIV-2 proteases and their respec-
tive N-terminal peptides. chain Fv fragment (scFv) in E. coli, which contains both
1696 variable domains joined by a flexible linking pep-
tide. Such scFv constructs, which retain the full antigenConclusion: A possible mechanism of HIV-protease in-
hibition by mAb1696 is proposed that could help the binding capacities, are the object of very active re-
search. Firstly, they are of interest for structural studiesdesign of inhibitors aimed at binding inactive monomeric
species. because they usually yield crystals diffracting to higher
resolution than the corresponding Fab fragments on
5 Correspondence: rezacova@img.cas.cz (P.R.), bentley@pasteur.fr
(G.A.B.) Key words: single-chain Fv; cross-reactivity; HIV protease; dissocia-
tive enzyme inhibitor; inhibition kinetics; crystal structure6 These authors contributed equally to this work.
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Figure 1. Inhibition of HIV-1 Pr and HIV-2 Pr
Activity by scFv1696
(a) The inhibition of HIV-1 Pr activity.
(b) The inhibition of HIV-2 Pr activity.
The initial reaction velocity (vi) of HIV-1 Pr
and HIV-2 Pr, normalized to the initial reaction
velocity in the absence of scFv1696 (v0), is
plotted as a function of scFv1696 concentra-
tion. The curves show the best fit of the tight
binding model [13] to the experimental data
(see text for details).
account of their smaller size and decreased interdomain following the rate of substrate cleavage using reverse-
phase HPLC (see Experimental Procedures). The kineticflexibility. Secondly, since they are expressed in bacte-
ria, they are also well suited for binding, mutagenesis data were used to estimate the initial reaction velocities
of HIV-1 Pr and HIV-2 Pr for each concentration of inhib-and protein engineering studies [12]. In this paper, we
report the three-dimensional structure at 2.70 A˚ resolu- iting scFv1696. These were normalized to the initial reac-
tion velocity in the absence of inhibitor and were plottedtion of a complex formed between scFv1696 and peptide
PQITLWQRR, whose sequence derives from the N termi- as a function of scFv1696 concentration (Figure 1). Inhi-
bition constants were evaluated by fitting the followingnus of the HIV-1 Pr. (The additional arginine residue
was added to the C terminus to increase solubility.) The equation, which describes the tight binding inhibition
model [13], to the experimental points of the graph:structure of the complexed scFv1696 is compared with
the free Fab1696 structure reported earlier [11]. On the
basis of the interactions seen in the complex, the cross- vi /v0  1  {[E]  [Ii ]  Kinh  √(([E]  [Ii ] 
reactivity between mAb1696 and the HIV-1 and HIV-2
Kinh)2  4[E][Ii ])}/(2[E])), (1)protease and their N-terminal peptides can be explained.
In addition, a mechanism of HIV Pr inhibition by mAb-
where [E] and [Ii ] are the protease concentration (held1696 is proposed that may help the design of alternative
constant) and the scFv1696 concentration, respectively,HIV protease inhibitors, aimed at dissociating the homo-
for the ith run; Kinh is the apparent inhibition constant, anddimeric viral enzyme.
v0 and vi are the initial reaction velocities for scFv1696
concentrations 0 and [Ii ], respectively.Results and Discussion
The inhibition constants, Kinh, thus obtained for the
scFv1696 were 0.6 nM for HIV-1 Pr and 5.5 nM for HIV-2Inhibition of HIV-1 Pr and HIV-2 Pr by scFv1696
Pr. The inhibition curves can also be used to obtainThe recombinant single-chain fragment scFv1696 was
the concentration of scFv1696 equivalent to the totalfound to have essentially the same inhibitory capacities
amount of active sites present in the reaction mixture.as those previously found for Fab1696 or for the com-
Thus, the calculated stoichiometry of the complexesplete antibody molecule [11]. Inhibition kinetics of the
protease in the presence of scFv1696 were measured by are 0.9:1 for the scFv1696/HIV-1 Pr and 1.0:1 for the
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peptide but is more open to the solvent at its C terminus,Table 1. Data Collection and Refinement Statistics
where the peptide, although not visible in this region,
Data Collection Statistics
presumably extends out from the antigen binding site.
Resolution The total molecular surface area buried upon complex
Shell (A˚) Unique Rmerge (%) Completeness (%) formation is 498 A˚2 for the peptide (representing 72%
30.00 5.80 1,285 5.4 94.8 of its total accessible surface area of the six N-terminal
5.80 4.61 1,296 5.4 98.0 residues) and 443 A˚2 for the antibody. Overall, the inter-
4.61 4.03 1,285 6.2 98.1 action is reminiscent of that seen in MHC-peptide com-
4.03 3.66 1,291 9.0 98.2
plexes, with a few residues from the antigen being buried3.66 3.40 1,285 10.4 98.5
in specificity pockets, serving as anchor residues, and3.40 3.20 1,259 13.3 97.7
others pointing toward the solvent, making only a few3.20 3.04 1,237 16.5 96.8
3.04 2.91 1,260 21.2 96.8 or no contacts [15].
2.91 2.80 1,254 26.3 95.7 The antigenic peptide interacts primarily with the
2.80 2.70 1,168 32.3 92.8 heavy chain of the antibody. This is reflected in the
All reflections 12,620 9.7 96.7
buried surface area per CDR upon complex formation,
Refinement Statistics where that from the heavy chain accounts for 70% of
the total buried surface. The hypervariable loops CDR-Resolution 30.0 A˚–2.70 A˚
Reflections 11,202 H1 and CDR-H2 of the antibody establish the largest
R factor 0.229 number of van der Waals contacts (Figure 3) and ac-
Rfree 0.287 count for eight of the nine hydrogen bonds seen in the
Number of amino acid residues 476
complex (Table 2). As seen in other antibody-peptideNumber of solvent molecules 53
complexes, hypervariable region CDR-L2 does not con-Number of protein nonhydrogen atoms 794
tact the antigen [16]. With the exception of peptide resi-Rmsd
Bond lengths 0.007 A˚ due Thr-P4, whose side chain points toward the exterior
Bond angles 1.44 of the antigen binding groove and does not make any
contact with the antibody, the remaining ordered resi-
dues from the peptide establish several contacts. The
most extensive polar interactions are made by Gln-P2,scFv1696/HIV-2 Pr complex, which agree with values
which is buried in a pocket formed by residues protrud-found previously for Fab1696 and IgG1696 [11].
ing from CDR-H1 and CDR-H2, losing 76% of its solvent-
accessible surface upon binding. As confirmed by theQuality of the Model and Overall Structure
low temperature factors for its main and side chainRefinement statistics from the scFv1696-peptide crystal
atoms, this residue is well stabilized by several polarstructure are given in Table 1. The final model includes
interactions with the antibody (Table 2). Two other resi-113 residues for the light chain and 120 residues for the
dues, Pro-P1 and Trp-P6, lose 68% and 81%, respec-heavy chain for each of the two scFv1696 molecules in
tively, of accessible surface area upon complex forma-the asymmetric unit. The two crystallographically inde-
tion. Pro-P1 and Trp-P6 are buried in pockets formedpendent complexes were tightly restrained during re-
by acidic residues Asp-H31 and Asp-H98, respectively,finement by imposing the noncrystallographic symmetry
and by hydrophobic residues Phe-L94 and Tyr-H47, re-relating them (see Experimental Procedures). All resi-
spectively. The formation of a hydrogen bond betweendues from the model fall into favorable or allowed re-
the secondary amino group of the N-terminal Pro-P1gions of the Ramachandran energy space, with the ex-
and the carbonyl group of Asp-H31 is consistent withception of Ala-51L, since this residue forms a  turn [14],
our observation that mAb1696 recognizes the maturewhich is characteristic of the unique canonical confor-
processed form of HIV-1 Pr, but not a precursor formmation of CDR-L2. Residues belonging to the hypervari-
containing 20 amino acids upstream from the cleavageable loops were well defined in the electron density map,
site. In the latter unprocessed form, the main chain sec-and the bound peptide could be unambiguously traced
ondary amide group of the proline residue is not cap-for six of its nine residues from Pro-P1 to Trp-P6 in both
able of hydrogen bond formation. Furthermore, the pres-complexes present in the asymmetric unit (Figure 2).
ence of a partially closed pocket containing negativelyAlthough some weak density is visible for main chain
charged residues could neutralize the positive chargeatoms of Gln-P7, this residue is not included in our
current model. Other missing residues from our model of the N terminus of the peptide or the mature protease.
belong to the flexible (Gly4Ser)3 linker, which connects Toward its C-terminal end, by contrast, recognition does
the C terminus of the light chain to the N terminus of not seem to be restricted by the length of the peptide,
the heavy chain. A total of 53 well-defined water mole- as shown by the broad reactivity between scFv1696 and
cules have been placed using difference maps. Of these, longer peptides like P1–P13 or the entire protease. The
32 are conserved between the two molecules. rather small number of well-ordered peptide residues
in the binding groove compared with other antibody-
peptide complexes is probably compensated by thePeptide-Antibody Interactions
large percentage of buried surface area upon complexIn the scFv1696-peptide complex, the antigenic peptide
formation. Furthermore, the large hydrophobic interac-adopts an extended conformation in a shallow groove
tion could offset a high entropic cost due to the highthat runs across the antigen binding site. This binding
groove is partially closed at the N-terminal end of the mobility of the peptide in solution [17].
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Figure 2. Stereo View from above the Antigen Binding Site
An omit-electron density map calculated with coefficients (Fo-Fc) and phases from the refined model without the peptide residues, contoured
at 2.5 rms level. The VH domain is in red, the VL domain is in violet, and the peptide and solvent molecules are in green.
Comparison between the Complexed scFv1696 plexed form. Superimposing the VH and VL domains
individually gives an rms difference in -carbon posi-and the Free Fab1696 Structures
To evaluate the contribution of conformational changes tions of 1.20 A˚ and 0.51 A˚, respectively. These differ-
ences result mainly from the adaptation of the CDRs towithin the antigen binding site upon formation of the
antibody-peptide complex, the scFv1696-peptide com- the antigen upon complex formation (see Figure 4). The
most conspicuous differences occur within CDR-H3,plex was compared with the variable dimer of the nonli-
ganded Fab1696 structure [11]. The crystallographic which undergoes a large conformational change upon
complex formation. When CDR-H3 is excluded from theasymmetric unit of the scFv1696 complex contains two
molecules that have been tightly restrained by the non- same pairwise comparison, the rmsd is 0.49 A˚. Indeed,
all -carbon atoms of the segment comprising residuescrystallographic symmetry relating them. Therefore, only
one molecule of scFv1696 is used here for comparison. Arg-H96–Glu-100A move by more than 2.0 A˚ between
their antigen-bound and free states, with the -carbonThe overall rms difference in the -carbon positions
of the variable dimers is 1.04 A˚ after superposition. Part of Tyr-H99 deviating by 7.0 A˚ (Figure 4). Two of these
residues, His-H97 and Asp-H98, establish direct van derof this deviation is due to a difference in the relative
orientation between the VH and VL domains of the com- Waals contacts with Pro-P1 from the antigenic peptide
(Figure 3). This large conformational change thus resultsplexed and nonliganded states of 1696. Thus, after su-
perimposing the VL domains of the two forms, the VH in the formation of a binding site with significantly differ-
ent topology from that of the free Fab1696 (Figures 4domain of the free 1696 variable dimer required an addi-
tional 4.3 rotation about its centroid (and a 0.2 A˚ transla- and 5). Hence, the recognition of the antigenic HIV-1 Pr
peptide by mAb1696 provides a clear example of antion) to give optimum superposition onto VH of the com-
Figure 3. Schematic View of the scFv1696-
Peptide Complex
All scFv1696 residues in contact with the pep-
tide are indicated.
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sponding atoms from the HIV-1 Pr with an overall rmsdTable 2. Polar Contacts in the scFv1696-HIV-1 Pr-Peptide
Complex of 1.8 A˚ (Figure 6). Nevertheless, the detailed conforma-
tion of the segment P1–P6 is different in the two struc-ScFv1696 Distance Distance
tures. In particular, the orientations of the side chainsPeptide Atom Atom scFv1 (A˚) scFv2 (A˚)
of the N- and C-terminal residues bear no similarity to
Pro P1 N Asp H31 O 2.40 2.79
those in the corresponding segment in the protease.Gln P2 N2 Thr H30 O 2.72 2.82
Gln P2 N Asp H31 O 3.24 3.23
Gln P2 O1 Ser H33 O 2.76 2.96
Cross-Reactivity with HIV-2 Pr N-TerminalGln P2 O1 Asn H52 O	1 3.21 3.07
Peptide PQFSLWKRGln P2 O1 Thr H52A N 2.89 2.71
Although mAb1696 was obtained by immunization withGln P2 N2 Thr H52A O1 2.98 3.22
Ile P3 N Ser H33 O 3.17 3.13 the entire HIV-1 Pr, it is nevertheless able to cross-react
Trp P6 N1 Gly L91 O 2.73 2.81 with HIV-2 Pr with a 3-fold increase in affinity [11]. In
addition, peptides containing the N-terminal region of
HIV-1 Pr, such as P1–P7 or P1–P13, are able to effec-
tively compete with the protease in binding to the an-induced fit mechanism for antibody-antigen recognition.
Other examples include the recognition of a hemaggluti- tibody.
Even though we have not succeeded so far in crys-nin peptide by antibody 17/9 [18] and the peptide 36–46
from the HIV-1 Pr [10], where large conformational tallizing the complex formed between mAb1696 and the
protease, it is of interest nevertheless to interpret thechanges in CDR-H3 are also associated with peptide
binding. Of note, the presence of glycine at position 100 cross-reactivity in light of our current crystal structure.
In the crystal structure of the scFv1696-HIV-1 Pr peptidein CDR-H3 of mAb1696 (as with Gly-H100B in mAb 17/9
and Gly-H100C in mAb F11.2.32) allows for a larger flexi- complex, several residues of the antigenic peptide are
deeply buried in complementary pockets formed by anti-bility of this hypervariable loop.
body residues. This would impose constraints on se-
quence variability at these positions in order for antigenConformation of Peptide
The six well-ordered residues from the antigenic peptide recognition to be maintained. The cross-reactivity of
1696 with the HIV-2 Pr peptide thus probably stemsadopt a rather extended structure, with several of its
backbone torsion angles (residues P2, P3, P4) lying in from the invariance between the two isolates of the four
residues situated at positions P1, P2, P5, and P6 of thethe  region of Ramachandran space. In contrast to
several other peptide-antibody complexes, where the protease sequence and the conservative substitutions
Ile-P3 → Phe and Thr-P4 → Ser, all of which lose morepeptide ligand adopts a more compact conformation
such as  turns [17], the HIV-1 Pr peptide has no intra- than 60% of their accessible surface area upon complex
formation. The substitution Gln-P7 → Lys and furthermolecular interactions that would stabilize the observed
conformation in solution. The conformation adopted by substitutions beyond position 7 would probably not af-
fect the interaction, although they could affect the un-the bound peptide is roughly similar to that seen in
the native protease, since the 20 main chain atoms of bound conformation of the antigen. Other amino acid
substitutions at position 4 should be tolerated since theresidues P1–P6 can be superimposed with the corre-
Figure 4. Comparison of the Variable Do-
mains of Noncomplexed Fab1696, PDB Entry
1c17, with the scFv1696 Peptide Complex
(a) A side view.
(b) Viewed from above the antigen binding
site.
The noncomplexed state is shown in blue,
the complexed state is shown in yellow, and
the peptide is shown in red. Superpositions
were made by optimizing the correspon-
dence between the VL domains.
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Figure 5. An Overhead View of the Topology
of the Antigen Binding Site
(a) The nonliganded Fab1696 scFv1696
complex.
(b) The liganded scFv1696 complex
The surfaces are color coded for electrostatic
potential in the range of 10 kBT(red) to 10
kBT (blue), where kB is the Boltzmann constant
and T is the absolute temperature. This figure
was prepared with GRASP [41].
side chain of this residue does not make direct contacts specific molecular complexes with both the HIV-1 and
HIV-2 proteases [11]. In addition, the stoichiometry ofwith the antibody. The substitution Ile-P3→ Phe retains
the hydrophobic character but must accommodate a the complex was evaluated as one protease monomer
per 1696 binding site. Since the structural similarity be-slightly larger side chain volume; the phenyl ring could,
however, provide favorable aromatic stacking interac- tween the bound antigenic peptide and the correspond-
ing segment of the native protease is only approximatetions with Trp-H50.
It is not clear from the crystal structure why mAb1696 (Figure 6), it is not possible to make an unequivocal
proposition for docking the protease itself onto the anti-suffers a loss of affinity toward HIV-2 Pr at lower pH while
that for HIV-1 is maintained [11], since the disordered gen binding site of scFv1696. Nevertheless, it is interest-
ing to use the orientation taken by the peptide withinresidue P7 (Gln → Lys) cannot be in close contact with
any acidic residue of the antigen binding site. The differ- the antigen binding site to generate possible models for
the HIV-protease in complex with the antibody. Theseent behavior as a function of pH could arise from the
difference in isoelectric points (theoretical values ob- models show that binding of the segment 1–6 by mAb
1696 is not possible in the active homodimer, mainlytained from the ExPASy server are 8.8 and 5.3 for HIV-1
Pr and HIV-2 Pr, respectively) and/or a difference in pH because of steric hindrance with the adjacent C-terminal
strand in the 4-stranded -pleated sheet. This is independence of the dimerization constant [19].
agreement with the measured stoichiometry of the com-
plex and also with binding studies in the presence ofMechanism of Inhibition
In our previous report, we showed, by using size-exclu- an active-site inhibitor, which suggest that 1696 binds
to the monomer [11].sion chromatography, that mAb1696 was able to form
Figure 6. Comparison of the Structures
Adopted by the Segment P1–P6 of HIV-1 Pr
The complex with scFv1696 is shown in yel-
low, and in the native protease (PDB entry
3hvp), it is shown in red. The superposition
was made by minimizing the rms difference in
the main chain atomic positions of the P2–P5
segment (rms difference 1.2 A˚).
HIV Protease Inhibition by a Monoclonal Antibody
893
Although docking one subunit only of the native prote- olysis of their polypeptide chains is required to ensure
correct virus assembly. By coupling mAb1696 with aase also generates steric hindrance, the N- and C-termi-
nal segments are probably disordered in the absence fluorescent dye or protein, one could use it as a probe
to elucidate the pathway that leads to the formation ofof the 4-stranded intermolecular antiparallel  sheet,
which maintains the dimeric structure. Indeed, a mature a mature virus within an infected cell. Since mAb1696
inhibits the HIV-Pr from both the HIV-1 and HIV-2 isolatesprotease monomer lacking residues 1–4 has been
shown by NMR to be significantly unfolded in the ab- with inhibition constants in the low nanomolar range, it
is therefore also a good candidate for studies aimed atsence of an active-site inhibitor [20]. It is possible that,
during immunization, the protease was presented in a controlling the viral infection with intracellularly ex-
pressed antibodies [22].partially denatured monomeric form and that mAb1696
was elicited against a nonnative structure of the enzyme.
This possibility has also been proposed for the anti- Experimental Procedures
HIV-1 Pr mAb F11.2.32 [10] and the anti-polymerase Taq
Inhibition of HIV-1 and HIV-2 Pr by scFv1696antibody TP7 [21], where the authors suggest that TP7
Inhibition of HIV Pr activity by scFv1696 was measured from thewould trap a conformer within a set of thermodynami-
cleavage rate of the substrate KARVNle-F(NO2)EANle followingcally accessible conformations of the enzyme. methods described in [23, 24]. Reactions were carried out in PBS
Two hypotheses thus emerge that could explain the buffer (pH 7.4) with 1% (v/v) Tween 20, 1% (w/v) BSA, 0.02% (v/v)
-mercaptoethanol, and 1 mM EDTA. Native HIV-2 Pr and the Q7K/inhibition of HIV-Pr activity by mAb1696. First, by bind-
L33I/L63I HIV-1 Pr mutant [25], which is highly resistant to autolysising to the N-terminal region of the native homodimeric
while still retaining all enzyme kinetic properties, were used forenzyme, which is located at the external surface in the
inhibition measurements. A fixed quantity of HIV Pr (70 nM and 125homodimeric enzyme structure and is thus relatively
nM for HIV-1 Pr and HIV-2 Pr, respectively) was first incubated with
accessible to antibody molecules, mAb1696 could dis- varying amounts of scFv1696 for 20 min at 37C. The reaction was
rupt the dimeric interface of the enzyme, leading to its then started by adding a constant amount of substrate solution
(final concentration 0.135 nM), and aliquots of the reaction mixture,dissociation. Second, the dimer-monomer equilibrium of
which were removed at fixed time intervals over a total period of 1the enzyme could be shifted toward inactive monomeric
hr, were stopped by the addition of 20% (v/v) TFA. The quantity ofspecies by capture of the latter by mAb1696. Although
cleavage product from each aliquot was determined by reverse-scFv1696 inhibits HIV-1 Pr nine times more efficiently
phase HPLC (Merck) using a VYDAC C18 column (4.5 mm 
 150
than it inhibits HIV-2 Pr, measurements of affinity con- mm) and a methanol/water gradient. Kinetic data were analyzed
stants by indirect ELISA, made under buffer conditions with ENZFITTER (version 1.0.3, R.L. Latherbarrow, Elsevier-Biosoft,
1987).identical to those of inhibition, show that mAb1696 and
Fab1696 have a 3-fold higher affinity for HIV-2 Pr in
comparison to HIV-1 Pr [11]. This apparent difference Cloning, Expression, Purification, and Complex Preparation
The coding sequences for VL and VH variable domains of mAb1696may be due to unaccounted systematic errors in either
were obtained by RT-PCR from the total mRNA of hybridoma 1696of the two kinds of experimental measurements. None-
cells, as had already been reported [11]. A corresponding scFvtheless, the two experiments are different, one being a
construct contains the 113 N-terminal residues from VL and thekinetic measure of inhibition and the other being a bind- 120 residues from VH, covalently linked together by the 15-residue
ing study under equilibrium conditions. Moreover, inhibi- (Gly4Ser)3 linker [26, 27]. For cloning, an intermediary vector based
on pBluescript was first assembled by sequential insertion of oligo-tion might conceivably begin before complete dissocia-
nucleotide duplexes, introducing an initiator ATG codon (as part oftion of the protease dimer has occurred if the initial
the NdeI restriction site) and the codon for the first VL residue, theinteraction with the antibody distorts the structure suffi-
linker sequence flanked by the last two VL residues and the firstciently. This interpretation would be more in line with
three VH residues, and unique restriction sites allowing cassette-the first hypothesis for the inhibition mechanism. like insertion of the VL (EcoRV-XhoI) and VH (PstI-EcoRI) domains.
Prior to the VH domain insertion, the C terminus of this fragment
was modified by PCR so that the terminator codon and an EcoRI
site could be introduced. Finally, the scFv1696-encoding regionBiological Implications
was cloned as the NdeI-EcoRI fragment into a T7 promoter-driven
expression plasmid.In this study, we have determined the three-dimensional
BL21(DE3) E. coli cells, when transformed with the above expres-structure of a bacterially expressed scFv of the anti-
sion plasmid, accumulated the scFv1696 product as insoluble inclu-
HIV-1 protease monoclonal antibody 1696 in complex sion bodies after induction with 1 mM IPTG. A 1-liter bacterial culture
with a peptide fragment that contains the linear epitope yielded typically about 10 g wet cells and about 1 g washed inclusion
bodies. Solubilization and refolding protocols were adapted fromof the viral enzyme. The broad reactivity of mAb1696,
[28]: inclusion bodies were solubilized in 50 mM Tris-HCl (pH 8.0)which allows it to bind to both HIV-1 Pr and HIV-2 Pr
with 2% N-lauroyl sarcosine (SLS, Sigma). The solution was vigor-with high affinity, derives from invariant amino acids or
ously stirred overnight at room temperature in the presence of 50conservative substitutions within the first six residues
M CuSO4 to oxidize SH groups by air. Urea was then added to 6 Mof the N-terminal segment of the two isolates. Most of concentration, and the SLS was removed by retention on anion-
these residues are deeply buried at the antibody-antigen exchange resin (Dovex). Refolding was performed by diluting the
denatured protein and by dialysing into 10 mM borate buffer (pHinterface and establish extensive contacts to the anti-
8.0). Purification included three chromatography steps, using DEAE-body. Using the peptide as a guide, a docking complex
Sephacel, Sephadex G-75, and Mono-Q 5/5 HR columns (Phar-of a whole protease monomer was generated that sup-
macia). The fraction content was checked throughout the purifica-ports the hypothesis that mAb1696 inhibits HIV-Pr by
tion by SDS-PAGE on a 15% acrylamide gel and analytical HPLC
favoring the dissociation of the active homodimer. gel filtration using a Superose 12 column (Pharmacia). Monomeric
For viruses such as HIV, which express polyprotein and dimeric forms of scFv1696 in equilibrium were observed. The
purified protein was transferred by dialysis into 10 mM Tris-HCl (pHprecursors, a careful regulation of the enzymatic prote-
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7.5), 5% glycerol and was stored at 25C. The yield was about 6 and water molecules excluded from the calculation. Antibody resi-
dues are numbered using the Kabat convention [40], preceded bymg of the purified scFv protein from 1 liter of bacterial culture.
L or H for light and heavy chain, respectively.
Crystallization and Data Collection
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